<code id='F99456E98A'></code><style id='F99456E98A'></style>

<acronym id='F99456E98A'></acronym>

<center id='F99456E98A'><center id='F99456E98A'><tfoot id='F99456E98A'></tfoot></center><abbr id='F99456E98A'><dir id='F99456E98A'><tfoot id='F99456E98A'></tfoot><noframes id='F99456E98A'>

<optgroup id='F99456E98A'><strike id='F99456E98A'><sup id='F99456E98A'></sup></strike><code id='F99456E98A'></code></optgroup>

<b id='F99456E98A'><label id='F99456E98A'><select id='F99456E98A'><dt id='F99456E98A'><span id='F99456E98A'></span></dt></select></label></b><u id='F99456E98A'></u>

~~<i id='F99456E98A'><strike id='F99456E98A'><tt id='F99456E98A'><pre id='F99456E98A'></pre></tt></strike></i>~~

Home» explore» focus

focus

focus

author：knowledge 2025-09-29 21:44:28 Page View：53

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

advertisement

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Weight loss drug Wegovy cuts risk of heart attacks in milestone trial
Next article： Medical leaders decry Supreme Court decision on affirmative action

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Anesthesiologist group: stop taking Ozempic before surgery

EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

Hospitals look to new technology to keep health care workers safe

Hospitals look to new technology to keep health care workers safe

AdobeOnedayinearly2020,justweeksbeforePhiladelphiaenteredlockdown,ThomasJeffersonUniversity’spublics

Moonlake's readout produced a cash windfall. Risks remain

Moonlake's readout produced a cash windfall. Risks remain

MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

Morphosys mixed study results for blood cancer drug

AdobeLONDON—AnexperimentalbloodcancerdrugfromMorphoSyshititsprimarytargetinapivotaltrial,thecompanya

read more